Want to see HK:2196 full AI Analyst Report?

Shanghai Fosun Pharmaceutical (Group) Co (2196) Price & Analysis

5 Followers

2196 Stock Chart & Stats

HK$19.63

-HK$0.04(-0.30%)

At close: Jan 09 4:00 PM EST

HK$19.63

-HK$0.04(-0.30%)

Day’s Range― - ―

52-Week RangeHK$14.90 - HK$29.00

Previous CloseN/A

Volume1.35M

Average Volume (3M)8.63M

Market Cap

HK$63.32B

Enterprise ValueHK$83.80B

Total Cash (Recent Filing)HK$15.29B

Total Debt (Recent Filing)HK$31.86B

Price to Earnings (P/E)17.0

Beta1.10

Next Earnings

Sep 01, 2026

EPS Estimate

0.43

Next Dividend Ex-DateN/A

Dividend Yield1.69%

Share Statistics

EPS (TTM)1.30

Shares Outstanding551,940,500

10 Day Avg. Volume5,166,409

30 Day Avg. Volume8,626,817

Financial Highlights & Ratios

PEG Ratio0.74

Price to Book (P/B)0.95

Price to Sales (P/S)1.15

P/FCF Ratio60.76

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

HK$29.80

Price Target Upside51.81% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

EPS Forecast (FY)1.48

Revenue Forecast (FY)HK$43.79B

Bulls Say, Bears Say

Bulls Say

Revenue ReboundA 158% TTM revenue rebound signals restored top-line momentum and improved commercial execution across products and channels. Durable revenue recovery suggests the company has regained market traction and can leverage scale for distribution, R&D prioritization, and sustained growth over the next several quarters.

Healthy MarginsRelatively high gross margin (~49%) and positive net margin (~8.1%) indicate structural pricing power and manufacturing efficiency versus peers. These margins provide a buffer against cost swings, support reinvestment in drug development and distribution, and underpin sustainable profitability if mix and cost control persist.

Diversified Healthcare ModelA multi‑leg business model (manufacturing, distribution, medical services) reduces single-segment risk and enables cross-selling, logistics scale, and captive demand for proprietary products. That structural diversification smooths revenue cyclicality and strengthens competitive positioning over a multi-quarter horizon.

Bears Say

Weak Cash ConversionFCF equal to roughly 24% of net income shows earnings are not translating efficiently into cash, reflecting working-capital or timing issues. Persistent weak cash conversion limits capacity to fund capex, M&A, dividends, or debt reduction and raises execution risk if operating needs or investment demands increase.

Moderate LeverageDebt-to-equity near 0.75 denotes meaningful leverage that reduces financial flexibility. In a capital-intensive healthcare environment this level constrains the ability to pursue large acquisitions or absorb shocks, and increases sensitivity to interest-cost fluctuations over the medium term.

Only Average Returns; Margin PressureA TTM ROE around 7% and declining EBITDA margins point to modest capital efficiency and rising cost or mix headwinds. Persistently average returns can limit internal funding for innovation and weaken long-run competitiveness versus higher-return peers unless margins or asset productivity improve.

Shanghai Fosun Pharmaceutical (Group) Co News

Fosun Pharma Subsidiary Wins Approval for New Traditional Chinese Medicine Granules

Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ) has shared an update. Shanghai Fosun Pharmaceutical said its subsidiary...

2d ago

Fosun Pharma Moves Ahead With Spin-Off Listing of Fosun Adgenvax in Hong Kong

Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ) just unveiled an update. Shanghai Fosun Pharmaceutical (Group) Co., Ltd....

5d ago

Fosun Pharma Shareholders Back AGM Resolutions and Final Dividend

Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ) has provided an announcement. Shanghai Fosun Pharmaceutical (Group) Co., Ltd.,...

15d ago

Fosun Pharma Sets Final 2025 Dividend and Withholding Tax Terms for H-Share Investors

Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ) has provided an update. Shanghai Fosun Pharmaceutical (Group) Co., Ltd....

15d ago

Fosun Pharma Wins NMPA Approval for New Pediatric Use of Luvometinib

Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ) has shared an announcement. Shanghai Fosun Pharmaceutical has announced that...

16d ago

Fosun Pharma Subsidiary Wins China Approval for Broad-Spectrum Levofloxacin Injection

Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ) has shared an announcement. Shanghai Fosun Pharmaceutical has announced that...

1M ago

Fosun Pharma Subsidiary Wins NMPA Acceptance for Innovative TCM Women’s Health Drug

Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ) has provided an announcement. Shanghai Fosun Pharmaceutical announced that the...

2M ago

Fosun Pharma Sets AGM to Approve 2025 Results and New Capital Mandates

Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ) has shared an update. Shanghai Fosun Pharmaceutical has called its...

2M ago

Fosun Pharma Calls 2026 H Shareholders Meeting on New H-Share Buyback Mandate

Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ) has shared an announcement. Shanghai Fosun Pharmaceutical has called a...

2M ago

Fosun Pharma Subsidiary Wins China Approval for Venlafaxine SR Tablets

An announcement from Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ) is now available. Shanghai Fosun Pharmaceutical said...

2M ago

Shanghai Fosun downgraded to Hold from Buy at HSBC

HSBC downgraded Shanghai Fosun to Hold from Buy with a price target of HK$20, down from HK$40. The...

3y ago

Syneos Health partners with Fosun Pharma USA to launch serplulimab

Syneos Health (SYNH) announced a strategic partnership with Fosun Pharma USA (SFOSF). As part of the partnership, Syneos...

3y ago

SYNH

2196 FAQ

What was Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s price range in the past 12 months?

Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H lowest stock price was HK$14.90 and its highest was HK$29.00 in the past 12 months.

What is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s market cap?

Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s market cap is HK$63.32B.

When is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s upcoming earnings report date?

Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s upcoming earnings report date is Sep 01, 2026 which is in 62 days.

How were Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s earnings last quarter?

Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H released its earnings results on Apr 28, 2026. The company reported HK$0.381 earnings per share for the quarter, beating the consensus estimate of HK$0.375 by HK$0.006.

Is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H overvalued?

According to Wall Street analysts Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H pay dividends?

Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H pays a Annually dividend of HK$0.45 which represents an annual dividend yield of 1.69%. See more information on Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H dividends here

What is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s EPS estimate?

Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s EPS estimate is 0.43.

How many shares outstanding does Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H have?

Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H has 551,940,500 shares outstanding.

What happened to Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s price movement after its last earnings report?

Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H reported an EPS of HK$0.381 in its last earnings report, beating expectations of HK$0.375. Following the earnings report the stock price went up 1.268%.

Which hedge fund is a major shareholder of Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H?

Currently, no hedge funds are holding shares in HK:2196

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Shanghai Fosun Pharmaceutical (Group) Co Stock Smart Score

Neutral

Fundamentals

Return on Equity

7.19%

Trailing 12-Months

Asset Growth

9.40%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a comprehensive healthcare enterprise, operating across Mainland China and international markets. Its principal activities include the research, development, production, and commercialization of pharmaceutical products. The company focuses on significant therapeutic domains such as oncology, immunology, metabolic disorders, gastrointestinal health, and central nervous system conditions. In addition to its drug offerings, Fosun Pharma provides medical devices and diagnostic solutions. Its multifaceted operations are organized into five key segments: pharmaceutical manufacturing, medical devices and diagnostics, healthcare services, pharmaceutical distribution and retail, and other business initiatives. This scope extends to managing healthcare facilities and hospitals, as well as the wholesale and retail distribution of medicines. The company was founded in 1994 and is headquartered in Shanghai, China.

Shanghai Fosun Pharmaceutical (Group) Co (2196) Earnings & Revenues

Historic Earnings Reports

2196 Stock 12 Month Forecast

Average Price Target

HK$29.80

▲(51.81% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"14":"HK$14","33":"HK$33","18.75":"HK$18.75","23.5":"HK$23.5","28.25":"HK$28.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":32,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$32.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":29.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$29.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$25.40</span>\n  </div></div>","useHTML":true}}],"tickPositions":[14,18.75,23.5,28.25,33],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.11,16.409230769230767,17.70846153846154,19.007692307692306,20.306923076923077,21.606153846153845,22.905384615384612,24.204615384615384,25.503846153846155,26.803076923076922,28.10230769230769,29.40153846153846,30.70076923076923,{"y":32,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.11,16.24,17.37,18.5,19.63,20.759999999999998,21.89,23.02,24.15,25.28,26.41,27.54,28.67,{"y":29.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.11,15.901538461538461,16.693076923076923,17.484615384615385,18.276153846153846,19.067692307692308,19.85923076923077,20.650769230769228,21.442307692307693,22.23384615384615,23.025384615384617,23.816923076923075,24.608461538461537,{"y":25.4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":16.556,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":18.84,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.88,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.78,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.82,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.38,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.55,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.87,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.34,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.46,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.11,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.15,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.11,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >